ArticleLeukemia2018

Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.

Laura N Eadie et al.PubMed ↗Publisher ↗

No numbers read from the abstract.